WALTHAM,
Mass., Aug. 2, 2022 /PRNewswire/ -- Syndax
Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage
biopharmaceutical company developing an innovative pipeline of
cancer therapies, today announced that it will report its second
quarter 2022 financial results on Monday,
August 8, after the close of the U.S. financial markets.
In connection with the earnings release, Syndax's management
will host a conference call and live audio webcast at 4:30 p.m. ET
on Monday, August 8, 2022 to discuss
the Company's financial results and provide a corporate update.
The live audio webcast and accompanying slides may be accessed
through the Events & Presentations page in the Investors
section of the Company's website. Alternatively, the conference
call may be accessed through the following:
Conference ID: SYNDAXQ2
Domestic Dial-in Number: 800-225-9448
International Dial-in Number: 203-518-9708
Live webcast:
https://www.veracast.com/webcasts/OpenEx/General/syndaxq2.cfm
For those unable to participate in the conference call or
webcast, a replay will be available on the Investors section of the
Company's website at www.syndax.com approximately 24 hours
after the conference call and will be available for 90 days
following the call.
About Syndax Pharmaceuticals,
Inc.
Syndax Pharmaceuticals is a clinical stage biopharmaceutical
company developing an innovative pipeline of cancer therapies.
Highlights of the Company's pipeline include revumenib (SNDX-5613),
a highly selective inhibitor of the Menin–MLL binding interaction,
and axatilimab, a monoclonal antibody that blocks the colony
stimulating factor 1 (CSF-1) receptor, both currently in pivotal
trials. For more information, please visit www.syndax.com or
follow the Company
on Twitter and LinkedIn.
Syndax Contact
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
View original
content:https://www.prnewswire.com/news-releases/syndax-to-announce-second-quarter-2022-financial-results-and-host-conference-call-and-webcast-on-august-8-2022-301597678.html
SOURCE Syndax Pharmaceuticals, Inc.